

#### COVID-19: What Have We Learned?

April G. Morris, FNP Hunter Holmes McGuire VA Medical Center Richmond, VA

#### Disclosures

All individuals in control of the content of continuing education activities provided by the Annenberg Center for Health Sciences at Eisenhower are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All staff at the Annenberg Center for Health Sciences at Eisenhower and the Gastroenterology and Hepatology Advanced Practice Providers have no relationships to disclose.



#### **April Morris, FNP-C**


Speaker Bureau: Gilead Sciences, Clinical Area-HCV

Speaker Bureau: Intercept, Clinical Area-PBC

Consultant: Intercept Pharmaceuticals, Clinical Area- PBC Consultant: AbbVie, Clinical Area- HCV

# **COVID Is Real**

- Global
  - Infections: 271,558,771
  - Deaths: 4,517,240
- United States
  - Infections: 38,923,013
  - Deaths: 634,320




https://covid19.who.int/region/amro/country/us accessed 9/02/2021. Photo credit: New York Times, accessed 9/02/2021

#### **COVID Care Costs**

- Projected \$202.6 billion lost revenue to US hospitals and health systems
- Projected global growth will shrink by 8%
- UN projects global economic cost of \$2 trillion

Kaye, Alan D, et al. *Clinical Anaesthesiology.* 17 Nov. 2020; Satiani, Bhagwan, and Carolyn A Davis, *Journal of vascular surgery.* vol. 72,6 (2020): 1856-1863; Colenda, Christopher C et al. *Academic medicine: journal of the Association of American Medical Colleges.* vol. 95,8 (2020): 1143-1145.

#### **COVID** Highlights Healthcare Disparities



https://www.cdc.gov/nchs/nvss/vsrr/covid19/health\_disparities.htm#RaceHispanicOriginAge.

#### **COVID Disproportionately Impacts BIPOC**

Rate ratios compared to White, Non- Hispanic persons	American Indian or Alaska Native, Non-Hispanic persons	Asian, Non- Hispanic persons	Black or African American, Non- Hispanic persons	Hispanic or Latino persons
Cases	1.7x	0.7x	1.1x	1.9x
Hospitalization	3.4x	1.0x	2.8x	2.8x
Death	2.4x	1.0x	2.0x	2.3x


#### **BIPOC: Black, Indigenous People of Color**

https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html.

#### COVID-19 Cases and Deaths by Race/Ethnicity


Cases by Race/Ethnicity:

Data from 31,349,273 cases. Race/Ethnicity was available for 20,193,105 (64%) cases.



Deaths by Race/Ethnicity:

Data from 530,922 deaths. Race/Ethnicity was available for 443,938 (83%) deaths.



Percentage of Deaths, All Age Groups

Percentage of the US Population , All Age Groups

#### https://covid.cdc.gov/covid-data-tracker/#demographics, accessed 9/4/2021

Percentage of Cases, All Age Groups


Percentage of the US Population . All Age Groups

# COVID-19 Cases and Death by Age Group

Cases by Age Group:


Percentage of the US Population

Data from 31,349,273 cases. Age group was available for 31,017,756 (98%) cases.



Deaths by Age Group:

Data from 530,922 deaths. Age group was available for 530,871 (99%) deaths.




https://covid.cdc.gov/covid-data-tracker/#demographics, accessed 9/4/2021

Percentage of the US Population

#### COVID-19 Cases and Death by Sex


Cases by Sex:

Data from 31,349,273 cases. Sex was available for 30,992,193 (98%) cases.



Deaths by Sex:

Data from 530,922 deaths. Sex was available for 529,722 (99%) deaths.



Percentage of Deaths, All Age Groups

Percentage of the US Population , All Age Groups


Percentage of Cases, All Age Groups

Percentage of the US Population , All Age Groups

https://covid.cdc.gov/covid-data-tracker/#demographics, accessed 9/4/2021

#### Underlying Medical Conditions Associated with High Risk for Severe COVID-19

#### Most Common Comorbidities




https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html

#### Telehealth to the Rescue?

• CMS eliminated restrictions and enhanced reimbursement for telehealth March 6, 2020

Telehealth claims volumes, compared to pre-Covid-19 levels (February 2020 = 1)<sup>1</sup>



https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/telehealth-a-quarter-trillion-dollar-post-covid-19-reality#.

# **Telehealth Disparities**

- 4/10 adults without internet in their home
- 3/10 adults earning \$30,000 or less do not own smartphone
- Adults over 65 owning smart phone or home broadband= 55-60%
- Rural broadband access= 63%
- BIPOC broadband access= 61-66%
- Approximately 14.5 million in US without internet access

https://www.pewresearch.org/fact-tank/2021/06/22/digital-divide-persists-even-as-americans-with-lower-incomes-make-gains-in-tech-adoption/;

https://catalyst.nejm.org/doi/full/10.1056/CAT.20.0123; https://healthpolicy.duke.edu/covid-19-and-rise-telehealth.

# **COVID** Vaccination

- Emergency authorization US:
  - December 11, 2020 Pfizer-BioNTech COVID-19 Vaccine
  - December 18, 2020 Moderna COVID-19 Vaccine
  - February 27, 2021 Janssen COVID-19 Vaccine



https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines.

#### Vaccine Efficacy

- Pfizer: 93.7% alpha
- Moderna: 94%
- Johnson & Johnson: 64% infection prevention
- Nearly 100% prevention of severe illness and hospitalization




Lopez Bernal et al. N Engl J Med. 2021 Jul 21. doi: 10.1056/NEJMoa2108891. Epub ahead of print. PMID: 34289274.

# Vaccine Efficacy-Delta Variant

- Vaccine efficacy is maintained against symptomatic disease caused by Delta
- Observational data suggests there may be reduced efficacy against all infection with Delta, as low as 50-67%
  - Short timeframes
  - Difficult to control for confounding
  - Positive PCR without clinical symptoms may not be meaningful

Fowlkes, MMWR, 2021; Nanduri, MMWR, 2021

#### Vaccine Uptake Lags



https://www.mayoclinic.org/coronavirus-covid-19/vaccine-tracker accessed 7/31/2021.

# Vaccine Safety

- Anaphylaxis: 2-5/1,000,000
- Thrombosis with thrombocytopenia syndrome (TTS)
  - J&J
  - 44 confirmed/14.2 million doses
- Guillain-Barre: J & J, preliminary report of 176
- Myocarditis/pericarditis: mRNA vaccines; 1377 cases reported, 798 confirmed by CDC and FDA
- Deaths: 7218 reports via VAERS over 340 million doses = 0.0020%

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html accessed 9/2/2021.

# **Recommended Therapies for COVID-19**

#### **Out-Patient**

- Monoclonal antibodies
  - Casirivimab-Imdevimab
  - Sotrovimab

#### Not Recommended:

Hydroxychloroquine Azithromycin Ivermectin Vitamin D Convalescent plasma

Beigal, NEJM, 2020; Kalil, NEJM, 2021; Marconi, Lancet Respir Med, 2021; RECOVERY, NEJM, 2021; RECOVERY, Lancet, 2021

#### **In-Patient**

- Remdesivir
  - Antiviral, inhibits replication
- Dexamethasone
  - Corticosteroid, reduces imflammatory response
- Tocilizumab (alt. Baricitinib)
  - Anti-IL6 monoclonal antibody with additive antiinflammatory activity

## **COVID** Lessons

- COVID is real
- COVID is costly
- COVID vaccines are safe and effective
- COVID vaccine uptake needs to improve
- Telehealth can happen
- COVID highlights disparities